International Journal of Endocrinology and Metabolism

Published by: Kowsar

Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

Authors Information
1 Medical Specialist Centre in Gliwice, Poland
2 Medical University of Silesia in Katowice, Poland
Article Notes and Dates
International Journal of Endocrinology and Metabolism: January 2018, 16 (1); e13008.Published Online: November 20, 2017
Article Type: Review Article; Received : May 11, 2017; Revised : September 18, 2017; Accepted : October 31, 2017

To Cite : Otto-Buczkowska E, Jainta N. Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?, Int J Endocrinol Metab. 2018 ;16(1):e13008. doi: 10.5812/ijem.13008.

Copyright: Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Insulin Resistance in Type 1 Diabetes
3. The Role of Obesity in Type 1 Diabetes
4. Adjunctive Treatment in Insulin Therapy
5. Biguanides
6. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT-2 Inhibitors)
7. Amylin (Islet Amyloid Polypeptide IAPP)
8. Incretin-Based Agents
9. Conclusions
  • 1. Ludvigsson J. Combination therapy for preservation of beta cell function in Type 1 diabetes: new attitudes and strategies are needed!. Immunol Lett. 2014;159(1-2):30-5. doi: 10.1016/j.imlet.2014.02.006. [PubMed: 24576850].
  • 2. Otto-Buczkowska E. Type 1 diabetes mellitus - what is news in the prevention and therapeutic strategies?. Med Matabol. 2013;17:84-90.
  • 3. Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. Nat Rev Endocrinol. 2015;11(5):289-97. doi: 10.1038/nrendo.2015.8. [PubMed: 25688000].
  • 4. Machnica L, Otto-Buczkowska E, Jarosz-Chobot P. Handbook of Type 1 Diabetes Mellitus: Etiology, Diagnosis, and Treatment. In: Aucoin L, Prideux T, editors. USA: Nova Science Publisher; 2010. The dilemmas in differential diagnosis of types of diabetes in adolescent patients; p. 467-79.
  • 5. Otto-Buczkowska E, Jarosz-Chobot P, Machnica L. Diabetes mellitus type 1, type 2 or type 1.5–dilemmas in making proper diagnosis. DDK/ECD. 2008;8(3):91-4.
  • 6. Pozzilli P, Guglielmi C. Double diabetes: a mixture of type 1 and type 2 diabetes in youth. Endocr Dev. 2009;14:151-66. doi: 10.1159/000207484. [PubMed: 19293582].
  • 7. Otto-Buczkowska E. Diabetes - but what? Diagnostic and own observations. Diabetologia po Dyplomie. 2015;12:20-7.
  • 8. Word Heath Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Geneva; 1999.
  • 9. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64(12):1629-39. doi: 10.1016/j.metabol.2015.09.002. [PubMed: 26455399].
  • 10. Szadkowska A, Pietrzak I, Mianowska B, Markuszewski L, Bodalska-Lipinska J, Bodalski J. [Insulin resistance in type 1 diabetic children and adolescents -- a simplified method of estimation]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(2):109-15. [PubMed: 16813715].
  • 11. Szadkowska A, Pietrzak I, Mianowska B, Bodalska-Lipinska J, Keenan HA, Toporowska-Kowalska E, et al. Insulin sensitivity in Type 1 diabetic children and adolescents. Diabet Med. 2008;25(3):282-8. doi: 10.1111/j.1464-5491.2007.02357.x. [PubMed: 18279410].
  • 12. Pietrzak I, Mianowska B, Gadzicka A, Mlynarski W, Szadkowska A. Blood pressure in children and adolescents with type 1 diabetes mellitus--the influence of body mass index and fat mass. Pediatr Endocrinol Diabetes Metab. 2009;15(4):240-5. [PubMed: 20455418].
  • 13. van Vliet M, Van der Heyden JC, Diamant M, Von Rosenstiel IA, Schindhelm RK, Aanstoot HJ, et al. Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic risk. J Pediatr. 2010;156(6):923-9. doi: 10.1016/j.jpeds.2009.12.017. [PubMed: 20223481].
  • 14. Bulum T, Duvnjak L. Insulin resistance in patients with type 1 diabetes: relationship with metabolic and inflammatory parameters. Acta Clin Croat. 2013;52(1):43-51. [PubMed: 23837272].
  • 15. Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab. 2007;18(2):52-7. doi: 10.1016/j.tem.2006.12.003. [PubMed: 17208448].
  • 16. Szadkowska A, Pietrzak I, Szlawska J, Kozera A, Gadzicka A, Mlynarski W. Abdominal obesity, metabolic syndrome in type 1 diabetic children and adolescents. Pediatr Endocrinol Diabetes Metab. 2009;15(4):233-9. [PubMed: 20455417].
  • 17. Otto-Buczkowska E, Dryzalowski M. Metabolicsyndrome in youngpatients. Pediatr Endocrinol Diabetes Metab. 2015;21(1):32-6. doi: 10.18544/PEDM-21.01.0022. [PubMed: 26901043].
  • 18. Luczynski W, Szypowska A, Bossowski A, Ramotowska A, Recko P, Rembinska M, et al. [Overweight, obesity and metabolic syndrome in children with type 1 diabetes melllitus]. Pediatr Endocrinol Diabetes Metab. 2010;16(2):83-8. [PubMed: 20813084].
  • 19. Luczynski W, Szypowska A, Glowinska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. Eur J Pediatr. 2011;170(7):891-8. doi: 10.1007/s00431-010-1372-7. [PubMed: 21140273].
  • 20. Bode BW, Garg SK. The Emerging Role of Adjunctive Noninsulin Antihyperglycemic Therapy in the Management of Type 1 Diabetes. Endocr Pract. 2016;22(2):220-30. doi: 10.4158/EP15869.RA. [PubMed: 26484403].
  • 21. Lebovitz HE. Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(6):326-34. doi: 10.1038/nrendo.2010.49. [PubMed: 20404854].
  • 22. Otto-Buczkowska E, Machnica L. The perspectives of adjunctive drugs usage in the treatment of glucose metabolism disturbances in adolescent patients. Pediatr Endocrinol Diabetes Metab. 2009;15(4):260-5. [PubMed: 20455421].
  • 23. Otto-Buczkowska E, Nowowiejska B, Jarosz-Chobot P, Stanczyk J. [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?]. Przegl Lek. 2009;66(7):388-93. [PubMed: 20043582].
  • 24. Otto-Buczkowska E, Machnica L. The perspectives of adjunctive drugs usage in the treatment of glucose metabolism disturbances in adolescent patients. Pediatr Endocrinol Diabetes Metab. 2009;15(4):260-5.
  • 25. Frandsen CS, Dejgaard TF, Madsbad S. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol. 2016;4(9):766-80. doi: 10.1016/S2213-8587(16)00039-5. [PubMed: 26969516].
  • 26. Gao YQ, Gao M, Xue Y. Treatment of diabetes in children. Exp Ther Med. 2016;11(4):1168-72. doi: 10.3892/etm.2016.3039. [PubMed: 27073417].
  • 27. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in Type 1 diabetes. Diabet Med. 2013;30(2):179-88. doi: 10.1111/j.1464-5491.2012.03744.x. [PubMed: 22804102].
  • 28. Otto-Buczkowska E. Metformin addend to insulin therapy for type 1 diabetes mellitus - based on literature and own experience. Medica Rev. 2010;8:338-42.
  • 29. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53(5):809-20. doi: 10.1007/s00125-009-1636-9. [PubMed: 20057994].
  • 30. Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol. 2009;105(3):145-9. doi: 10.1111/j.1742-7843.2009.00380.x. [PubMed: 19496776].
  • 31. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11(10):966-77. doi: 10.1111/j.1463-1326.2009.01079.x. [PubMed: 19558610].
  • 32. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev. 2009;(1). CD006691. doi: 10.1002/14651858.CD006691.pub2. [PubMed: 19160294].
  • 33. Bacha F, Klinepeter Bartz S. Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes. Pediatr Diabetes. 2016;17(8):545-58. doi: 10.1111/pedi.12337. [PubMed: 26592507].
  • 34. Anderson J, Pena AS, Sullivan T, Gent R, D'Arcy B, Olds T, et al. Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. BMC Pediatr. 2013;13:108. doi: 10.1186/1471-2431-13-108. [PubMed: 23865839].
  • 35. Libman IM, Miller KM, DiMeglio LA. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314:2241-50.
  • 36. Ficek R, Chudek J, Wiecek A. Cukrzyca w populacji wieku rozwojowego - co nowego?. In: Otto-Buczkowska E, editor. Wroclaw; 2009. Blocking the re-absorption of glucose in the renal tubules as a new potential treatment for diabetes; p. 244-50.
  • 37. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-7. doi: 10.1038/ki.2009.87. [PubMed: 19357717].
  • 38. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25(3):671-81. doi: 10.1185/03007990802710422. [PubMed: 19232040].
  • 39. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11(2):79-88. doi: 10.1111/j.1463-1326.2008.00982.x. [PubMed: 19125776].
  • 40. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34-42. doi: 10.1210/jc.2009-0473. [PubMed: 19892839].
  • 41. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142. doi: 10.1186/s12933-015-0297-x. [PubMed: 26474563].
  • 42. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412-9. doi: 10.2337/dc13-2955. [PubMed: 25271207].
  • 43. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23(6):875-82. doi: 10.1517/13543784.2014.909407. [PubMed: 24746173].
  • 44. Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17(10):928-35. doi: 10.1111/dom.12494. [PubMed: 26080652].
  • 45. Tamez HE, Tamez AL, Garza LA, Hernandez MI, Polanco AC. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78. doi: 10.1186/s40200-015-0210-x. [PubMed: 26457255].
  • 46. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66(7):975-87. doi: 10.1111/jphp.12223. [PubMed: 24533859].
  • 47. Cheng ST, Chen L, Li SY, Mayoux E, Leung PS. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic beta-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016;11(1). e0147391. doi: 10.1371/journal.pone.0147391. [PubMed: 26807719].
  • 48. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?. Can J Diabetes. 2014;38(5):356-63. doi: 10.1016/j.jcjd.2014.05.006. [PubMed: 25192954].
  • 49. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. [PubMed: 24334175].
  • 50. Skrtic M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24(1):96-103. doi: 10.1097/MNH.0000000000000084. [PubMed: 25470017].
  • 51. Kitada K, Nakano D, Ohsaki H, Hitomi H, Minamino T, Yatabe J, et al. Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy. J Diabetes Complications. 2014;28(5):604-11. doi: 10.1016/j.jdiacomp.2014.05.010. [PubMed: 24996978].
  • 52. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194-204. doi: 10.1152/ajprenal.00520.2013. [PubMed: 24226524].
  • 53. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. doi: 10.1186/1475-2840-13-28. [PubMed: 24475922].
  • 54. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687-93. doi: 10.2337/dc15-0843. [PubMed: 26078479].
  • 55. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016;22(6):753-62. doi: 10.4158/EP161292.PS. [PubMed: 27082665].
  • 56. Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs. 2015;24(10):1381-7. doi: 10.1517/13543784.2015.1061501. [PubMed: 26288025].
  • 57. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015;38(7):1181-8. doi: 10.2337/dc14-2806. [PubMed: 26049551].
  • 58. Biester T, Aschemeier B, Fath M, Frey M, Scheerer MF, Kordonouri O, et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and ss-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab. 2017;19(11):1635-9. doi: 10.1111/dom.12975. [PubMed: 28417527].
  • 59. Mietlicki-Baase EG. Amylin-mediated control of glycemia, energy balance, and cognition. Physiol Behav. 2016;162:130-40. doi: 10.1016/j.physbeh.2016.02.034. [PubMed: 26922873].
  • 60. Otto-Buczkowska E, Jarosz-Chobot P, Machnica L. The role of amylin in glucose homeostasis regulation and possible future usage in adolescents with type 1 diabetes. Diabetologia Doswiadczalna i Kliniczna. 2009;9(2):41-0.
  • 61. Edelman SV. Optimizing diabetes treatment using an amylin analogue. Diabetes Educ. 2008;34 Suppl 1:4S-10S. doi: 10.1177/0145721707313939. [PubMed: 18268000].
  • 62. Otto-Buczkowska E, Mazur-Dworzecka U, Dworzecki T. [Role of amylin in glucose homeostasis and its perspective use in diabetes management]. Przegl Lek. 2008;65(3):135-9. [PubMed: 18624122].
  • 63. Riddle MC, Yuen KC, de Bruin TW, Herrmann K, Xu J, Ohman P, et al. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab. 2015;17(9):904-7. doi: 10.1111/dom.12504. [PubMed: 26040429].
  • 64. Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract. 2009;15(7):689-95. doi: 10.4158/EP09044.ORR1. [PubMed: 19546056].
  • 65. Chase HP, Lutz K, Pencek R, Zhang B, Porter L. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr. 2009;155(3):369-73. doi: 10.1016/j.jpeds.2009.03.012. [PubMed: 19464026].
  • 66. Hassan K, Heptulla RA. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatr Diabetes. 2009;10(4):264-8. doi: 10.1111/j.1399-5448.2008.00490.x. [PubMed: 19140902].
  • 67. Kishiyama CM, Burdick PL, Cobry EC, Gage VL, Messer LH, McFann K, et al. A pilot trial of pramlintide home usage in adolescents with type 1 diabetes. Pediatrics. 2009;124(5):1344-7. doi: 10.1542/peds.2008-3750. [PubMed: 19858155].
  • 68. Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, et al. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013;125(3):136-44. doi: 10.3810/pgm.2013.05.2635. [PubMed: 23748514].
  • 69. Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG. Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials. Adv Ther. 2016;33(5):848-61. doi: 10.1007/s12325-016-0326-5. [PubMed: 27071768].
  • 70. Ramkissoon CM, Aufderheide B, Bequette BW, Palerm CC. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes. J Diabetes Sci Technol. 2014;8(3):529-42. doi: 10.1177/1932296813517323. [PubMed: 24876617].
  • 71. Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012;35(10):1994-9. doi: 10.2337/dc12-0330. [PubMed: 22815298].
  • 72. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439-51. doi: 10.1517/14656566.2011.581663. [PubMed: 21564002].
  • 73. Meier JJ, Nauck MA. Incretin-based therapies: where will we be 50 years from now?. Diabetologia. 2015;58(8):1745-50. doi: 10.1007/s00125-015-3608-6. [PubMed: 25994073].
  • 74. Otto-Buczkowska E. Cukrzyca w populacji wieku rozwojowego - co nowego?. In: Otto-Buczkowska E, editor. 2009. Incretin action of certain hormones axis entero-pancreatic and their role in the metabolism of glucose; p. 61-8.
  • 75. Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55-8. doi: 10.1016/j.diabres.2013.01.020. [PubMed: 23490599].
  • 76. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol. 2014;8(5):1011-7. doi: 10.1177/1932296814542153. [PubMed: 25030181].
  • 77. Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open. 2015;5(4). e007791. doi: 10.1136/bmjopen-2015-007791. [PubMed: 25838513].
  • 78. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221-32. doi: 10.1016/S2213-8587(15)00436-2. [PubMed: 26656289].
  • 79. Rizzo M, Rizvi AA, Sesti G. Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes Obes Metab. 2017;19(5):613-4. doi: 10.1111/dom.12883. [PubMed: 28098425].
  • 80. Jung GS, Jeon JH, Choe MS, Kim SW, Lee IK, Kim MK, et al. Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice. Diabetes Metab J. 2016;40(3):211-21. doi: 10.4093/dmj.2016.40.3.211. [PubMed: 27098503].
  • 81. Salheen SM, Panchapakesan U, Pollock CA, Woodman OL. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose. PLoS One. 2015;10(11). e0143941. doi: 10.1371/journal.pone.0143941. [PubMed: 26618855].
  • 82. Zhao Y, Yang L, Wang X, Zhou Z. The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev. 2014;30(8):646-53. doi: 10.1002/dmrr.2530. [PubMed: 24446278].
  • 83. Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. [PubMed: 23439744].
  • 84. Underland LJ, Ilkowitz JT, Katikaneni R, Dowd A, Heptulla RA. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. J Diabetes Sci Technol. 2017;11(3):602-10. doi: 10.1177/1932296817699847. [PubMed: 28349708].
  • 85. Schopman JE, Hoekstra JB, Frier BM, Ackermans MT, de Sonnaville JJ, Stades AM, et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab. 2015;17(6):546-53. doi: 10.1111/dom.12453. [PubMed: 25694217].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Search Relations:



Create Citiaion Alert via Google Reader